The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Emerging Issues in Androgen Replacement Therapy1
Abstract
THE LAST FEW years in the androgen field can only be described in the words of Charles Dickens, as “… the age of wisdom, (and) … the age of foolishness.” Some of the recent advances in the androgen field have been truly spectacular. Our understanding of androgen action and the pathophysiology of androgen insensitivity syndromes has been greatly enhanced by the characterization of the androgen receptor and the 5-α reductase genes. The development of 5-α reductase inhibitors has made available a new class of therapeutic agents for the treatment of a number of androgen-dependent clinical disorders including benign prostatic hyperplasia. Several attractive testosterone delivery systems have been approved, and many more are under development (1–6). Clinical trials have established the effectiveness of testosterone-induced azoospermia and/or severe oligozoospermia in inducing reversible contraception in healthy men (7–9). The rationale for anabolic applications of replacement and supraphysiological doses of testosterone has been strengthened by well-controlled clinical trials (10, 11). On the other hand, several recent trends in androgen use are alarming. Because a substantial portion of the androgen market is underground, exact estimates of androgen use in the United States are not available. However, audits of direct and indirect sales indicate that the androgen sales in this country are growing 20–30% each year. There is reason to believe that a substantial part of the overall androgen market involves the illicit use of testosterone for unapproved indications, particularly for muscle building by athletes and recreational body builders. The use of testosterone in human immunodeficiency virus (HIV)-infected men is growing, although clinical trials to examine the effectiveness of testosterone in reversing HIV-wasting syndrome are still in progress. It is distressing that a significant proportion of hypogonadal men continue to be undiagnosed, diagnosed late, or inappropriately treated. Thus a paradoxical situation has developed in which testosterone replacement therapy continues to be underutilized or inappropriately used for legitimate indications, while its use for unapproved indications continues to expand. The objective of this review is to highlight the new androgen formulations, and suggest pragmatic regimens for the institution and monitoring of testosterone replacement therapy. In addition, the review will also discuss the rationale for the proposed anabolic applications of androgen therapy in wasting states. Testosterone is well absorbed after its oral administration but is quickly degraded during its passage through the liver. Therefore, it is not possible to achieve sustained blood levels of testosterone after oral administration of crystalline testosterone. 17-α alkylated derivatives of testosterone are relatively resistant to hepatic degradation and can be given orally; however, because of the potential for hepatotoxicity, these formulations are not recommended for clinical use. The esterification of the testosterone molecule at the 17-β-hydroxy position makes the molecule hydrophobic and extends its duration of action. Deesterification of testosterone is not a limiting factor in determining its duration of action; the plasma half-lives and clearance rates for testosterone and testosterone enanthate are similar. It is the slow release of the hydrophobic testosterone ester from its oily depot in the muscle that accounts for its extended duration. The longer the side chain, the greater the hydrophobicity of the ester and the greater the duration of action. Thus testosterone enanthate and cypionate with longer side chains have longer duration of action than testosterone propionate. After intramuscular administration of 200 mg testosterone enanthate, serum testosterone levels rise rapidly into the high normal or even the supraphysiological range within 24 h and then gradually decline into the hypogonadal range over the next 2 weeks (12, 13). Therefore, a bimonthly regimen of testosterone enanthate or cypionate results in highs and lows in serum testosterone levels that are attended by similar changes in the patient’s mood, sexual desire and activity, and energy level. The kinetics of testosterone enanthate and cypionate are identical. Serum levels of estradiol and dihydrotestosterone (metabolites that are derived by conversion from testosterone) are normal if testosterone replacement is physiological. Two transdermal testosterone systems are now commercially available: a scrotal testosterone patch (Testoderm, ALZA Corporation, Palo Alto, CA) and a permeation-enhanced nongenital patch (Androderm, SmithKline Beecham Pharmaceuticals, Collegeville, PA). The scrotal transdermal system, when applied daily on the scrotal skin, can produce mid-normal serum testosterone levels in hypogonadal men 4–8 h after application of the patch followed by gradual decrease in serum testosterone levels over the next 24 h (2). S
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T. J., Tricker, R., Shirazi, A., & Casaburi, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350101 · Cited by 1,659
Self-citationBiological Actions of Androgens
MOORADIAN, A. D., MORLEY, J. E., & KORENMAN, S. G. (1987) · Endocrine Reviews · doi:10.1210/edrv-8-1-1 · Cited by 1,080
Cited by
Feldman, H. A., Longcope, C., Derby, C. A., Johannes, C. B., Araujo, A. B., Coviello, A. D., Bremner, W. J., & McKinlay, J. B. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8201 · Cited by 1,861
Self-citationLamberts, S. W. J., van den Beld, A. W., & van der Lely, A.-J. (1997) · Science · doi:10.1126/science.278.5337.419 · Cited by 980
Testosterone dose-response relationships in healthy young men
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., Chen, X., Yarasheski, K. E., Magliano, L., Dzekov, C., et al. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1172 · Cited by 967
Self-citationISSN exercise & sports nutrition review update: research & recommendations
Kerksick, C. M., Wilborn, C. D., Roberts, M. D., Smith-Ryan, A., Kleiner, S. M., Jäger, R., Collins, R., Cooke, M., Davis, J. N., Galvan, E., et al. (2018) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-018-0242-y · Cited by 945
Risks of testosterone-replacement therapy and recommendations for monitoring.
Rhoden, E. L., & Morgentaler, A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra022251 · Cited by 705
Metadata
- Authors
- Bhasin, S., & Bremner, W. J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1997-01
- Volume
- 82
- Issue
- 1
- Pages
- 3-8
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2081873302
- Cited by
- 160
- References
- 2
- FWCI
- 10.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging Issues in Androgen Replacement Therapy1. https://app.cochat.ai/papers/10.1210/jcem.82.1.3640
- The paper
- Bhasin, S., & Bremner, W. J. (1997). Emerging Issues in Androgen Replacement Therapy1. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jcem.82.1.3640
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.